Compositions and methods comprising binding proteins for adalimumab
Compositions and methods comprising proteins that bind specifically to adalimumab are disclosed herein. Adalimumab is a monoclonal antibody specific for the cytokine TNF-α and was developed to treat TNF-α mediated inflammatory diseases. In one aspect of the instant invention, the binding proteins are antibodies directed toward adalimumab. These antibodies, including binding fragments thereof, can be used in a clinical setting as well as for research and development. For example, these anti-adalimumab antibodies can be employed to neutralize adalimumab.
1. An isolated anti-adalimumab monoclonal antibody, or an antigen binding portion thereof, wherein said antibody is antibody 5A1-2A8, produced by a hybridoma having ATCC accession no. PTA-8513, or an antigen-binding portion thereof.
2. The antibody, or an antigen binding portion thereof, of claim 1 which is a Fab fragment or a single chain antibody.
3. A method of detecting adalimumab in a sample, said method comprising
contacting said sample with the antibody, or antigen-binding portion thereof, of claim 1 under conditions suitable for antibody-antigen complex formation, and
detecting a presence of the antibody-antigen complex formation, wherein detection of the complex indicates the presence of adalimumab in the sample.
4. The method of claim 3 , wherein said detecting is selected from the group consisting of EIA (enzyme immunoassay), ELISA (enzyme linked immunosorbent assay), RIA (radioimmunoassay), indirect competitive immunoassay, direct competitive immunoassay, non-competitive immunoassay, sandwich immunoassay, and agglutination assay.
5. A kit comprising isolated anti-adalimumab monoclonal antibody 5A1-2A8, produced by a hybridoma having ATCC Accession No. PTA-8513, or an antigen-binding portion thereof.
6. The kit of claim 5 further comprising a control antibody, wherein said control antibody does not react with adalimumab or a fragment thereof.
7. A hybridoma cell line deposited under ATCC accession number PTA-8512.
8. An isolated anti-adalimumab monoclonal antibody, or an antigen binding portion thereof, wherein said antibody is 1H11-2E10, produced by a hybridoma having ATCC accession No. PTA-8512, or an antigen-binding portion thereof.
9. The antibody, or an antigen binding portion thereof, of claim 8 which is a Fab fragment or a single chain antibody.
10. A method of detecting adalimumab in a sample, said method comprising
contacting said sample with the antibody, or antigen-binding portion thereof, of claim 8 under conditions suitable for antibody-antigen complex formation, and
detecting a presence of the antibody-antigen complex formation, wherein detection of the complex indicates the presence of adalimumab in the sample.
11. The method of claim 10 , wherein said detecting is selected from the group consisting of EIA (enzyme immunoassay), ELISA (enzyme linked immunosorbent assay), RIA (radioimmunoassay), indirect competitive immunoassay, direct competitive immunoassay, non-competitive immunoassay, sandwich immunoassay, and agglutination assay.
12. A kit comprising isolated anti-adalimumab monoclonal antibody 1H11-2E10, produced by a hybridoma having ATCC Accession No. PTA-8512, or an antigen-binding portion thereof.
13. The kit of claim 12 further comprising a control antibody, wherein said control antibody does not react with adalimumab or a fragment thereof.
14. A hybridoma cell line deposited under ATCC accession number PTA-8513.